Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | FPR2 | P25090 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | IL2 | P60568 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1310365 | 1.00 | KMT2A (0.57) | KMT2AFPR2ALDH1A1GAAANPEP | |
| SCHEMBL1308795 | 0.92 | ATM (0.53) | KMT2AFPR2ANPEPATML3MBTL1 | |
| SCHEMBL1308801 | 0.92 | ATM (0.53) | KMT2AFPR2ANPEPATML3MBTL1 | |
| SCHEMBL1307925 | 0.90 | KMT2A (0.67) | KMT2AFPR2ALDH1A1GAACA2 | |
| SCHEMBL3685242 | 0.90 | KMT2A (0.67) | KMT2AFPR2ALDH1A1GAACA2 | |
| SCHEMBL1310698 | 0.83 | KMT2A (0.49) | KMT2AFPR2ALDH1A1CA2ALOX15 | |
| SCHEMBL1310695 | 0.83 | KMT2A (0.49) | KMT2AFPR2ALDH1A1CA2ALOX15 | |
| SCHEMBL1310417 | 0.81 | KMT2A (0.55) | KMT2AFPR2ATML3MBTL1 | |
| SCHEMBL1310421 | 0.81 | KMT2A (0.55) | KMT2AFPR2ATML3MBTL1 | |
| SCHEMBL8772939 | 0.80 | LDHA (0.45) | KMT2AFPR2ALDH1A1CA2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877968-B2 | Melanocortin receptor modulators, process for preparing them and use there in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-11-04 | — | — | US | disclosed |
| EP-2352728-B1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2014-05-21 | — | — | EP | disclosed |
| US-20120301458-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2010099217-A1 | MODULATION OF NEUROGENESIS USING D-CYCLOSERINE COMBINATIONS | BRAINCELLS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010052255-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120301458-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | KMT2A 4671/4885FPR2 113/4885ALDH1A1 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.